12,372 trials
Neisseria Meningitidis · Haemophilus Influenzae Type b
Primary: Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value — 120; 144; 127; 113…
Smoking · Tobacco Use Disorder
Primary: Point Prevalence Smoking Abstinence at 12 Weeks: the Number of Patients Who Refrained From Smoking at 12 Weeks — 27 Participants
Multiple Sclerosis
Primary: The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial…
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Endometrial Cancer
Primary: Number of Participants With Palmar-plantar Erythrodysesthesia (PPE) — 2; 3; 3; 3 participants — p=<0.05
Stage IIIA Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Overall Survival (OS) — 11.4; 10.5 Months — p=0.54
Contraception
Primary: Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population, — 2.554 Pregnancy Rate
Asthma
Primary: Time to First Asthma Exacerbation — 225.1; 249.5; 227.2 days — p=0.6625
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Psoriasis Vulgaris
Primary: Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8 — 183; 147; 37 Participants
Hepatitis B, Chronic
Primary: Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss — 39; 40; 70 Participants — p=0.860
Acromegaly
Primary: The Percentage of Subjects or Their Partners That Are Competent to Self-administer Somatuline Autogel at the End of the Study, (Week 24/Early Termination), as Assessed…
Epilepsy
Primary: The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase — 0.375 proportion of subjects
Thromboembolism · Arthroplasty, Replacement, Hip
Primary: Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 53; 75; 60 Participants — p=0.5648
Cystic Fibrosis · Lung Infection · Pseudomonas Aeruginosa
Primary: Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28 — 1.41; 3.22 Units on a scale — p=0.433
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint — 12.76; 13.56; -6.38; -5.29 Units on a scale — p=0.006